Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

This study is comparing two treatment approaches for women with hormone receptor-positive, HER2-negative advanced breast cancer: a combination of ribociclib (a targeted oral drug) plus a hormone-blocking drug versus chemotherapy followed by hormone therapy. **You may be eligible if...** - You are a woman aged 18 or older - You have breast cancer that has come back or spread (metastatic) - Your breast cancer tests positive for estrogen or progesterone receptors, and negative for HER2 - Your general health is good enough to tolerate treatment (ECOG score 0–2) **You may NOT be eligible if...** - You have HER2-positive breast cancer - Your breast cancer is hormone receptor-negative - You have severe health conditions that would make treatment unsafe Talk to your doctor to see if this trial is right for you.